紫杉醇
多西紫杉醇
紫杉烷
卵巢癌
卵巢癌
流式细胞术
体内
癌症研究
细胞培养
卵巢肿瘤
体外
分泌物
生物
细胞
癌症
内科学
医学
内分泌学
免疫学
生物化学
乳腺癌
生物技术
遗传学
作者
Christian Marth,Alain G. Zeimet,Martin Widschwendter,Christoph Ludescher,J. Kærn,Claes G. Tropé,Günther Gastl,Günter Daxenbichler,O Dapunt
出处
期刊:PubMed
日期:1997-09-01
卷期号:57 (17): 3818-22
被引量:1
摘要
Taxanes represent a new class of antineoplastic agents that are being evaluated in several malignant tumors; they have been shown to induce a high remission rate and to prolong survival in ovarian cancer patients. However, CA-125 has been suggested to be an unreliable marker for monitoring response to paclitaxel therapy. Therefore, we were interested in whether taxanes may directly modulate CA-125 expression. Human ovarian carcinoma cell lines OVCAR-3, HOC-7, SKOV-6, 2780, 2774, and HTB-77 were treated with paclitaxel or docetaxel. Secreted, surface-associated, and cytosolic CA-125 were estimated by means of a sandwich solid-phase RIA or by immuno-flow cytometry. In addition to in vitro antiproliferative activity, paclitaxel and docetaxel augmented the expression of the tumor marker CA-125 in the three ovarian carcinoma cell lines, OVCAR-3, HOC-7, and SKOV-6, constitutively expressing this tumor marker. The three CA-125-negative cell lines, 2780, 2774, and HTB-77, did not respond to taxane treatment by expressing this tumor marker, although their proliferation was markedly inhibited. The taxane-mediated induction of CA-125 was found to be dependent on intact protein and RNA biosynthesis. However, CA-125 concentration was increased in the supernatant medium only and not on cell surface or cytosol. Our results demonstrate an in vitro activation of ovarian carcinoma cells in terms of CA-125 secretion by taxanes. This may explain the CA-125 fluctuations observed in vivo under paclitaxel treatment and may indicate that CA-125 is not a reliable tumor marker during taxane chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI